President Trump Proposes High Tariffs on Imported Drugs

Proposed tariffs of 100% and 200% by 2028 and 2029 aim to shift pharmaceutical manufacturing to the U.S.

Updated on Sept. 28, 2026 in Healthcare

Bold flat-color editorial illustration of pharmaceutical reaction vessels, symbolizing the industrial focus of proposed federal drug manufacturing tariffs. — President Trump proposed high tariffs on imported pharmaceuticals by 2029 to incentivize domestic drug manufacturing, potentially increasing costs for consumers. AI Illustration. Upload story photo >

Live Poll

Do you believe taxing imported drugs is worth the potential increase in your personal healthcare costs?

President Trump has proposed significant tariffs on imported drugs, reaching 100% by 2028 and 200% by 2029. The policy intends to incentivize drug manufacturers to move production infrastructure to the United States.

Why it matters

These tariffs are designed to encourage domestic pharmaceutical production, though they may lead to the removal of certain medications from the U.S. market. Additionally, increased costs could force patients to pay significantly higher out-of-pocket expenses for essential treatments.

The proposal targets 100% tariffs by 2028 and 200% by 2029, a move that contrasts with current global supply chains. Establishing the required domestic infrastructure to support this shift would necessitate multi-billion dollar capital investments.

The players

President Donald Trump

He is the current President of the United States who announced the proposed tariff structure to shift pharmaceutical production.

The details

The proposal targets the complex supply chains required for drug production, which currently rely on multi-company partnerships for chemical components, packaging, and coloring. For families like those in Eagle Mountain, Utah, whose children require treatments costing over $300,000 annually, the potential for higher expenses amid current $25,000 insurance premiums creates significant financial uncertainty.

The 100% tariff on imported drugs is proposed to take effect in 2028.
The 200% tariff on imported drugs is proposed to take effect in 2029.

Market Landscape

This policy marks a departure from modern globalized pharmaceutical supply chains and follows a pattern set by the Tariff Act of 1930. The shift aims to prioritize domestic manufacturing at the potential cost of industry-wide disruption.

Consumers could face significantly higher out-of-pocket costs for essential medications as manufacturers navigate the increased tariff expenses. Patients with rare conditions already paying high insurance premiums may see their access to specific life-saving treatments restricted.

The takeaway

Patients should prepare for potential changes in drug availability and costs by reviewing their current insurance coverage and treatment options. The transition to domestic manufacturing will likely remain a critical focal point for the pharmaceutical industry over the coming years.